BRAIN CANCER

Latest News

FDA Grants FORE8394 Orphan Drug Designation for Primary Brain/CNS Malignancies
FDA Grants FORE8394 Orphan Drug Designation for Primary Brain/CNS Malignancies

March 22nd 2023

The first orphan drug designation from the FDA has been received by FORE Biotherapeutics and for the FORE8394 program for patients with primary brain and central nervous system malignancies.

FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade Glioma
FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade Glioma

March 16th 2023

Vorasidenib Delays Disease Progression or Death in IDH+ Low-Grade Glioma
Vorasidenib Delays Disease Progression or Death in IDH+ Low-Grade Glioma

March 14th 2023

FDA Gives Orphan Drug Designation to Temferon for Glioblastoma Multiforme
FDA Gives Orphan Drug Designation to Temferon for Glioblastoma Multiforme

March 8th 2023

FDA Okays Phase 2 Study of Azeliragon for Patients With Glioblastoma
FDA Okays Phase 2 Study of Azeliragon for Patients With Glioblastoma

February 27th 2023

More News